Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.18 USD
Change Today +0.09 / 8.26%
Volume 67.5K
PDII On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Open
$1.12
Previous Close
$1.09
Day High
$1.20
Day Low
$1.07
52 Week High
05/29/14 - $5.05
52 Week Low
05/1/15 - $1.00
Market Cap
19.1M
Average Volume 10 Days
51.4K
EPS TTM
$-0.77
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment’s services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

775 Employees
Last Reported Date: 03/5/15
Founded in 1986

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $736.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $86.2K
President of Sales Services
Total Annual Compensation: $386.3K
Compensation as of Fiscal Year 2014.

pdi inc (PDII) Key Developments

PDI, Inc. Proposes to Amend the Certificate of Incorporation

PDI, Inc. proposed to amend the company's certificate of incorporation to increase the number of authorized shares of common stock from 40,000,000 to 100,000,000 at the AGM to be held on June 03, 2015.

Prolias Technologies Files Suit against PDI Inc

Prolias Technologies, Inc. has filed suit against PDI Inc. PDI is alleged to have engaged breach of contract, breach of covenant of good faith and fair dealing, intentional interference with contract, and breach of fiduciary duty. The complaint was filed in Superior Court of New Jersey for the County of Morris (Docket number 899/15). The complaint alleges that PDI breached a Joint Venture Agreement with Prolias to validate, commercialize and ultimately monetize 'Thymira', a microRNA based thyroid cancer test. According to the complaint, PDI breached its obligations under the Agreement and committed a variety of torts by, among other wrongs, failing to effectively and timely validate "Thymira", buying a competitor and developing its competitive product in lieu of 'Thymira', interfering with the license agreement between Cornell and the Prolias Technologies, and, upon information and belief, attempting to purchase the license agreement from Cornell directly and to the exclusion of the Prolias Technologies. The complaint further alleges that PDI practically usurped the name 'Thymira' from Prolias by naming its competitive product 'Thyramir'.

PDI, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

PDI, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net revenues were $28.9 million, down from $35.9 million reported for the same period last year. The loss from continuing operations before income tax was $9.4 million versus $2.1 million for the fourth quarter of 2013. Net loss from continuing operations was $0.30 per diluted share, compared to $0.14 net loss per share in fourth quarter 2013. For the year, the company’s net revenue was $120 million. The loss from continuing operations before income tax was $14.1 million versus $1.5 million in 2013. The company provided earnings guidance for the year 2015, the company expected total revenue of $133 million to $140 million including: commercial services revenue of $121 million to $125 million, representing 2% to 5% growth over the prior year; and Interpace Diagnostics revenue representing approximately 10% of total net revenue. The company expected adjusted operating loss of $17 million to $19 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $1.18 USD +0.09

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDII.
View Industry Companies
 

Industry Analysis

PDII

Industry Average

Valuation PDII Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit www.pdi-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.